AbbVie reports positive Phase 3 atogepant results in menstrual migraine
Atogepant met the primary and all eight ranked secondary endpoints in the Phase 3 Luna study.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.